Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models

Elana Thieme, Vi Lam, Nur Bruss, BS, Fei Xu, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Alexey Danilov, MD, Tingting Liu

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-134957

Published: 2020

Journal Articles

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Tingting Liu, Fei Xu, Elana Thieme, Vi Lam, Guang Fan, MD PhD, Liana Nikolaenko, MD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Olga Danilova, Alexey Danilov, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-134951

Published: 2020

Journal Articles

Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia

James T Dibb, DO, Nicola Long, Christopher A. Eide, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD

Blood (2020) 136 (Supplement 1): 12–14.

https://doi.org/10.1182/blood-2020-137674

Published: 2020

Journal Articles

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Rucha V Modak, PhD, Sara J Gosline, Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Ted Laderas, PhD, Guanming Wu, PhD, Paul Piehowski, Paul.Piehowski@pnnl.gov, Stephen E Kurtz, PhD, Christopher A. Eide, Jeffrey W. Tyner, PhD, Karin Rodland, rodland@ohsu.edu, Shannon K. McWeeney, PhD, Anupriya Agarwal, PhD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-141686

Published: 2020

Journal Articles

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, MS, Nicola Long, Jessica Leonard, MD, Bill H. Chang, MD PhD, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 3950.

https://doi.org/10.1182/blood-2019-131288

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Alisa Damnernsawad, PhD, Tamilla Nechiporuk, PhD, Daniel Bottomly, MS, Stephen E Kurtz, PhD, Christopher A. Eide, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 2557.

https://doi.org/10.1182/blood-2019-128877

Published: 2019

Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 878.

https://doi.org/10.1182/blood-2019-126020

Published: 2019

Journal Articles

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Tamilla Nechiporuk, PhD, Alisa Damnernsawad, PhD, Daniel Bottomly, MS, Quinlan Morrow, BS, Suyoun Choi, Sofia Beer, Stephen E Kurtz, PhD, Shannon K. McWeeney, PhD, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 1395.

https://doi.org/10.1182/blood-2019-129117

Published: 2019

Journal Articles

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Stephen E Kurtz, PhD, Cristina E. Tognon, PhD, Leylah M. Drusbosky, PhD, Robinson Vidva, B.Tech, Yugandhara Narvekar, M.Sc., Ashish Kumar Agrawal, B.V.Sc, A.H., Saji Gera, M.Tech, Samiksha Avinash Prasad, M.Sc., Vijayashree P Shyamasundar, M.Sc., Gaurav Singh Tunwer, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1540.

https://doi.org/10.1182/blood-2018-99-115284

Published: 2018

Journal Articles

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Leylah M. Drusbosky, PhD, Diwyanshu Sahu, M.Sc., Robinson Vidva, B.Tech, Shweta Kapoor, M.Sc., Humera Azam, M.Sc., Rajeev Kumar, B.Tech, Padmagiri G Chickdipatti, B.E, Nithya T Raveendaran, M.Tech, Reshma P Gopi, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Christopher R. Cogle, MD

Blood (2018) 132 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2018-99-115678

Published: 2018

Journal Articles

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

Haijiao Zhang, Beth Wilmot, PhD, Daniel Bottomly, Stephen E Kurtz, PhD, Christopher A. Eide, Alisa Damnernsawad, Kyle Romine, Shyam Patel, Brian J. Druker, MD, Schannon K Mcweeney, Ravi Majeti, MD PhD, Jeffrey W. Tyner, PhD

Blood (2018) 132 (Supplement 1): 175.

https://doi.org/10.1182/blood-2018-175

Published: 2018

Journal Articles

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Hongying Zhang, MD, PhD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Taryn McLaughlin, MS, Alexey V Danilov, MD PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Stephen Howell, MD, William G Rice, PhD

Blood (2018) 132 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2018-99-117285

Published: 2018

Journal Articles

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Brian S. White, PhD, Suleiman A. Khan, PhD, Muhammad Ammad-ud-din, PhD, Swapnil Potdar, MSc, Mike J Mason, PhD, Cristina E. Tognon, PhD, Brian J. Druker, MD, Caroline A Heckman, PhD, Olli Kallioniemi, MD PhD, Stephen E Kurtz, PhD, Kimmo Porkka, MD PhD, Jeffrey W. Tyner, PhD, Tero Aittokallio, PhD, Krister Wennerberg, PhD, Justin Guinney, PhD

Blood (2018) 132 (Supplement 1): 2763.

https://doi.org/10.1182/blood-2018-99-111916

Published: 2018

Journal Articles

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Stephen E Kurtz, PhD, Christopher A. Eide, Narain P. Dubey, Andy Kaempf, Shannon K. McWeeney, PhD, Cristina E. Tognon, PhD, Motomi Mori, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Anupriya Agarwal, PhD

Blood (2018) 132 (Supplement 1): 2726.

https://doi.org/10.1182/blood-2018-99-117537

Published: 2018

Journal Articles

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Christopher A. Eide, Stephen E Kurtz, PhD, Andy Kaempf, Cristina E. Tognon, PhD, Motomi Mori, PhD, Max J. Gordon, MD, Jeffrey W. Tyner, PhD, Alexey V Danilov, MD PhD, Brian J. Druker, MD

Blood (2018) 132 (Supplement 1): 214.

https://doi.org/10.1182/blood-2018-99-117468

Published: 2018

Journal Articles

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, Samantha L Savage, Anna M. Reister Schultz, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Motomi Mori, PhD, Elie Traer, MD PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 2068.

https://doi.org/10.1182/blood.V130.Suppl_1.2068.2068

Published: 2017

Journal Articles

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Arko Das, MS, Krishna K Tiwari, BT, Vishwas Joseph, MS, Subrat Mohapatra, MS, Neelesh Lunkad, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3907.

https://doi.org/10.1182/blood.V130.Suppl_1.3907.3907

Published: 2017

Journal Articles

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Anjanasree V. Lakshminarayana, BE, Vijayashree P. Shyamasundar, MS, Ashish Kumar Agrawal, BS, Anay Talawdekar, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3908.

https://doi.org/10.1182/blood.V130.Suppl_1.3908.3908

Published: 2017

Journal Articles

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Madeleine Turcotte, MS, Paul Castillo, MD, Robinson Vidva, BT, Saji Gera, MT, Mohammed Sauban, BE, Priyanka Bhargav, BE, Punya Deep, MS, Shweta Kapoor, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3909.

https://doi.org/10.1182/blood.V130.Suppl_1.3909.3909

Published: 2017

Journal Articles

CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples

Stephen E Kurtz, PhD, Beth Wilmot, PhD, Shannon Mcweeney, PhD, Andrea Local, PhD, Hongying Zhang, MD, Stephen Howell, MD, William Rice, PhD, Brian J. Druker, MD, Jeffrey W. Tyner, PhD

Blood (2017) 130 (Supplement 1): 4626.

https://doi.org/10.1182/blood.V130.Suppl_1.4626.4626

Published: 2017

NARROW

Pharmacologic Inhibition of B Cell-Receptor-Associated Kinases with CG-806 Induces Apoptosis and Metabolic Reprogramming in Aggressive Non-Hodgkin Lymphoma (NHL) Models

Pharmacologic Targeting MCL1 with AZD5991 Induces Apoptosis and Mitochondrial Dysfunction in Non-Hodgkin Lymphoma (NHL) Cells

Patterns of Venetoclax Sensitivity in Chronic Lymphocytic Leukemia

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Simultaneous Kinase Inhibition with Ibrutinib and BCL2 Inhibition with Venetoclax As a Therapeutic Strategy for Acute Lymphoblastic Leukemia

Genome-Wide CRISPR Screening Identifies MAPK and Mtorc Pathways As Regulators of Sorafenib Resistance in Acute Myeloid Leukemia

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Genome-Wide CRISPR Screening in Acute Myeloid Leukemia Cells Identifies Genes in the PI3K/AKT/mTOR and MEK/ERK Pathways That Define Sensitivity to Trametinib

Predicting Response to BET Inhibitor in Combination with Palbociclib / Sorafenib Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to Dasatinib Using a Computational Model and Its Validation: A Beat AML Project Study

Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML

Combining p38MAPK Inhibitors with a Second Targeted Agent Enhances Blockade of Inflammatory Signaling-Mediated Survival in Acute Myeloid Leukemia Cells

Dual Inhibition of Bruton's Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias

Identification of Effective Combinations of Targeted Drugs for DNMT3A and NPM1 Mutated Acute Myeloid Leukemia

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to CDK4/6 Inhibitors and Combinations Using a Computational Biology Model and Its Validation: A Beat AML Project Study

CG '806, a First-in-Class Pan-FLT3/BTK Inhibitor, Exhibits Potent Growth Inhibition As a Single Agent and in Combination with a BET Bromodomain Inhibitor or a Bcl2 Inhibitor on Primary AML and CLL Patient Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only